Kineret

ApprovedSmall molecule

Amgen

Kineret is one of 152 small molecule programs targeting Familial Mediterranean Fever. It is currently in Approved.

Indications

Total Trials

Active Trials

151

Competitors

Pipeline

Status by Indication[3][1]

Indication

Familial Mediterranean FeverActive, not recruiting

Macrophage Activation SyndromeActive, not recruiting

Familial Cold UrticariaActive, not recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

Type 1 Diabetes MellitusActive, not recruiting

Chronic Granulomatous DiseaseActive, not recruiting

Familial Mediterranean FeverPhase 3

Active, not recruiting

Macrophage Activation SyndromePhase 1

Active, not recruiting

Familial Cold UrticariaPhase 1

Active, not recruiting

Chronic Lymphocytic LeukemiaPhase 1

Active, not recruiting

Rheumatoid ArthritisApproved

Active, not recruiting

Type 1 Diabetes MellitusPhase 2

Active, not recruiting

Chronic Granulomatous DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Kineret

Amgen

Approved

1 2

Rituxan

Roche

Preclinical

61 3

Actemra

Cimzia

30 5

Enbrel

IImmunex

Preclinical

64 6

Arcoxia

Novartis

Preclinical

4 7

Ilaris

Novartis

Preclinical

3 8

Actos

Takeda

Preclinical

2 9

Celexa

AbbVie

Preclinical

1 10

Rituxan

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Familial Mediterranean Fever1 trial

Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever

Completed·SSheba Medical Center·Phase 3·NCT01705756·25 enrolled

Chronic Lymphocytic Leukemia1 trial

Anakinra in Previously Untreated Chronic Lymphocytic Leukemia Patients

Unknown status·—·Phase 1·NCT04691765·12 enrolled

Macrophage Activation Syndrome1 trial

Treatment of Macrophage Activation Syndrome (MAS) With Anakinra

Terminated·UUniversity of Alabama at Birmingham·Phase 1·NCT02780583·9 enrolled

LAM1 trial

Personalized Therapies in Inflammatory Complex Disease

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT03651518·32 enrolled

Dialysis Patients1 trial

Inflammation, Proteolysis and IL-1 Beta Receptor Inhibition in Chronic Hemodialysis Patients

Completed·VVanderbilt University·N/A·NCT00420290·31 enrolled

6 more indications

Type 1 Diabetes Mellitus1 trial

Effect of Anakinra on Insulin Sensitivity in Type 1 Diabetes Mellitus

Unknown status·RRadboud University Medical Center·Phase 2·NCT01285245·16 enrolled

Chronic Granulomatous Disease1 trial

IL-1 Receptor Inhibitor for Granulomatous Complications in Patients With Chronic Granulomatous Disease

Completed·FFederal Research Institute of Pediatric Hematology, Oncology and Immunology·Phase 1·NCT04136028·13 enrolled

Familial cold urticaria1 trial

The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria

Completed·NNova Scotia Health Authority·Phase 1·NCT00214851·8 enrolled

Double-blind1 trial

A Dose-Block Randomized, Placebo Controlled (Double-blind), Active Controlled(Open-label), Dose-escalation Study

Completed·HHandok Inc.·Phase 1·NCT02175056·58 enrolled

Rheumatoid Arthritis1 trial

Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire

Completed· Amgen logo

Amgen·Phase 4·NCT00121043

GIST1 trial

REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations

Completed· Amgen logo

Amgen··NCT00121056

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Kineret. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Kineret compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Kineret. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Amgen

Kineret

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Familial Mediterranean Fever1 trial

Chronic Lymphocytic Leukemia1 trial

Macrophage Activation Syndrome1 trial

LAM1 trial

Dialysis Patients1 trial

Type 1 Diabetes Mellitus1 trial

Chronic Granulomatous Disease1 trial

Familial cold urticaria1 trial

Double-blind1 trial

Rheumatoid Arthritis1 trial

GIST1 trial

References

Drug Info

Quick Facts

Related News